0.02(0.98%) Volume: 10,713 10:27AM EST| Market Cap : 74.77 M | Enterprise Value : 64 M | P/E (TTM) : | P/B : 1.15 |
|---|
AVDL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVDL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 1.09 |
AVDL's Cash-to-Debt is ranked lower than
77% of the 1078 Companies in the Global Biotechnology industry. ( Industry Median: 64.02 vs. AVDL: 1.09 ) Ranked among companies with meaningful Cash-to-Debt only. |
AVDL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 9.7 Max: 352.34 Current: 1.09 |
| Equity-to-Asset | 0.24 |
AVDL's Equity-to-Asset is ranked lower than
86% of the 763 Companies in the Global Biotechnology industry. ( Industry Median: 0.69 vs. AVDL: 0.24 ) Ranked among companies with meaningful Equity-to-Asset only. |
AVDL'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.32 Med: 0.48 Max: 0.8 Current: 0.24 |
| Debt-to-Equity | 1.74 |
AVDL's Debt-to-Equity is ranked lower than
89% of the 500 Companies in the Global Biotechnology industry. ( Industry Median: 0.28 vs. AVDL: 1.74 ) Ranked among companies with meaningful Debt-to-Equity only. |
AVDL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -8.99 Med: 0.06 Max: 10.98 Current: 1.74 |
| Piotroski F-Score: 2 |
|
| Altman Z-Score: -0.81 |
|
| Beneish M-Score: -3.93 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | -63.97 |
AVDL's Operating Margin % is ranked higher than
66% of the 792 Companies in the Global Biotechnology industry. ( Industry Median: -113.97 vs. AVDL: -63.97 ) Ranked among companies with meaningful Operating Margin % only. |
AVDL'
s Operating Margin % Range Over the Past 10 Years
Min: -611.75 Med: -28.65 Max: 58.79 Current: -63.97 |
| Net Margin % | -33.89 |
AVDL's Net Margin % is ranked higher than
71% of the 792 Companies in the Global Biotechnology industry. ( Industry Median: -111.91 vs. AVDL: -33.89 ) Ranked among companies with meaningful Net Margin % only. |
AVDL'
s Net Margin % Range Over the Past 10 Years
Min: -1027.16 Med: -27.32 Max: 39.41 Current: -33.89 |
| ROE % | -48.01 |
AVDL's ROE % is ranked higher than
76% of the 989 Companies in the Global Biotechnology industry. ( Industry Median: -42.82 vs. AVDL: -48.01 ) Ranked among companies with meaningful ROE % only. |
AVDL'
s ROE % Range Over the Past 10 Years
Min: -1111.21 Med: -23.96 Max: 106.97 Current: -48.01 |
| ROA % | -13.72 |
AVDL's ROA % is ranked higher than
78% of the 1084 Companies in the Global Biotechnology industry. ( Industry Median: -34.77 vs. AVDL: -13.72 ) Ranked among companies with meaningful ROA % only. |
AVDL'
s ROA % Range Over the Past 10 Years
Min: -58.85 Med: -12.24 Max: 27.38 Current: -13.72 |
| ROC (Joel Greenblatt) % | -1070.76 |
AVDL's ROC (Joel Greenblatt) % is ranked higher than
98% of the 1036 Companies in the Global Biotechnology industry. ( Industry Median: -521.46 vs. AVDL: -1070.76 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
AVDL'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4050.11 Med: -42.51 Max: 3538.48 Current: -1070.76 |
| 3-Year Revenue Growth Rate | 115.60 |
AVDL's 3-Year Revenue Growth Rate is ranked higher than
95% of the 651 Companies in the Global Biotechnology industry. ( Industry Median: 1.10 vs. AVDL: 115.60 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
AVDL'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -52.4 Med: 0.8 Max: 181.1 Current: 115.6 |
| Charles Brandes 4,808,493 sh (+45.35%) | Jim Simons 781,800 sh (-31.70%) |
| Charles Brandes 4,970,106 sh (+3.36%) Jim Simons 1,049,070 sh (+34.19%) |
| Charles Brandes 6,335,548 sh (+27.47%) | Jim Simons 579,135 sh (-44.80%) |
| Charles Brandes 7,119,054 sh (+12.37%) Jim Simons 621,500 sh (+7.32%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Action |
Impact | Price Range (Average)* |
Change from Average | Comment | Current Shares |
|---|
What is Peter Lynch Charts )| Industry: | Biotechnology » Biotechnology NAICS: 325414 SIC: 2836 | |
|---|---|---|
| Compare: | OSL:BGBIO, XKRX:007630, MIL:MLM, BOM:531349, XKRX:046210, NAS:SELB, LSE:OBD, NAS:KIN, NAS:TYME, NAS:MBIO, OTCPK:OSIR, XKRX:064550, AMEX:XXII, ROCO:6575, WAR:SLV, NAS:TORC, ASX:PNV, NAS:NERV, NAS:ASNS, TSE:4571 » details | |
| Traded in other countries: | AWK1.Germany, | |
| Headquarter Location: | Ireland |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PB Ratio | 1.15 |
AVDL's PB Ratio is ranked higher than
71% of the 962 Companies in the Global Biotechnology industry. ( Industry Median: 4.10 vs. AVDL: 1.15 ) Ranked among companies with meaningful PB Ratio only. |
AVDL'
s PB Ratio Range Over the Past 10 Years
Min: 1.13 Med: 4.63 Max: 71.87 Current: 1.15 |
| PS Ratio | 0.66 |
AVDL's PS Ratio is ranked higher than
92% of the 726 Companies in the Global Biotechnology industry. ( Industry Median: 9999.00 vs. AVDL: 0.66 ) Ranked among companies with meaningful PS Ratio only. |
AVDL'
s PS Ratio Range Over the Past 10 Years
Min: 0.66 Med: 4.24 Max: 799.47 Current: 0.66 |
| EV-to-Revenue | 0.55 |
AVDL's EV-to-Revenue is ranked higher than
96% of the 771 Companies in the Global Biotechnology industry. ( Industry Median: 13.69 vs. AVDL: 0.55 ) Ranked among companies with meaningful EV-to-Revenue only. |
AVDL'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5 Med: 3.7 Max: 248 Current: 0.55 |
| Current Ratio | 3.15 |
AVDL's Current Ratio is ranked lower than
60% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.46 vs. AVDL: 3.15 ) Ranked among companies with meaningful Current Ratio only. |
AVDL'
s Current Ratio Range Over the Past 10 Years
Min: 0.57 Med: 2.77 Max: 6.76 Current: 3.15 |
| Quick Ratio | 3.02 |
AVDL's Quick Ratio is ranked lower than
59% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.18 vs. AVDL: 3.02 ) Ranked among companies with meaningful Quick Ratio only. |
AVDL'
s Quick Ratio Range Over the Past 10 Years
Min: 0.52 Med: 2.63 Max: 6.7 Current: 3.02 |
| Days Inventory | 125.65 |
AVDL's Days Inventory is ranked higher than
52% of the 481 Companies in the Global Biotechnology industry. ( Industry Median: 125.55 vs. AVDL: 125.65 ) Ranked among companies with meaningful Days Inventory only. |
AVDL'
s Days Inventory Range Over the Past 10 Years
Min: 51.05 Med: 100.4 Max: 1457.72 Current: 125.65 |
| Days Sales Outstanding | 30.31 |
AVDL's Days Sales Outstanding is ranked higher than
72% of the 668 Companies in the Global Biotechnology industry. ( Industry Median: 64.17 vs. AVDL: 30.31 ) Ranked among companies with meaningful Days Sales Outstanding only. |
AVDL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.8 Med: 69.78 Max: 541.87 Current: 30.31 |
| Days Payable | 240.89 |
AVDL's Days Payable is ranked higher than
82% of the 536 Companies in the Global Biotechnology industry. ( Industry Median: 63.91 vs. AVDL: 240.89 ) Ranked among companies with meaningful Days Payable only. |
AVDL'
s Days Payable Range Over the Past 10 Years
Min: 161.48 Med: 228.67 Max: 3311.63 Current: 240.89 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 21.20 |
AVDL's 3-Year Average Share Buyback Ratio is ranked higher than
100% of the 857 Companies in the Global Biotechnology industry. ( Industry Median: -13.40 vs. AVDL: 21.20 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
AVDL'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47.7 Med: -7.8 Max: 21.2 Current: 21.2 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Median-PS-Value | 0.16 |
AVDL's Price-to-Median-PS-Value is ranked higher than
87% of the 678 Companies in the Global Biotechnology industry. ( Industry Median: 0.92 vs. AVDL: 0.16 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
AVDL'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16 Med: 1.33 Max: 187.5 Current: 0.16 |
| Earnings Yield (Greenblatt) % | -45.53 |
AVDL's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 1081 Companies in the Global Biotechnology industry. ( Industry Median: -7.73 vs. AVDL: -45.53 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
AVDL'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -46 Med: -7.35 Max: 40.1 Current: -45.53 |
| Revenue (TTM) (Mil) $ | 117.10 |
|---|---|
| EPS (TTM) $ | -1.02 |
| Beta | 2.16 |
| Volatility | 36.32% |
| 52-Week Range $ | 1.69 - 8.55 |
| Shares Outstanding (Mil) | 37.01 (ADR) |
| Dec18 | Dec19 | Dec20 | |
|---|---|---|---|
| Revenue (Mil $) | 118 | 134 | 217 |
| EBIT (Mil $) | |||
| EBITDA (Mil $) | |||
| EPS ($) | 1.65 | -1.10 | 0.16 |
| EPS without NRI ($) | 1.65 | -1.10 | 0.16 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | ||
| Dividends per Share ($) | |||
|
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP